pharmaceutical company developing treatments for autism spectrum disorders with FDA approval

Industry Spotlight: EuMentis Therapeutics

About EuMentis

EuMentis Therapeutics Inc. is a privately held clinical stage pharmaceutical company founded in 2019 with the mission to develop novel therapies to improve the quality of life of patients suffering from central nervous system disorders.

EuMentis is evaluating other neuropsychiatric conditions that involve glutamate or dopamine imbalance for low-trapping NMDA antagonists, EM-221, or other novel compounds derived from its platforms to treat symptoms of pediatric neuropsychiatric disorders such as Tourette Syndrome and ASD.

Developing a Noncompetitive NMDA Antagonist for Autism Spectrum Disorder

So far, there are no approved medications for Autism Spectrum Disorders (ASD), although an imbalance in regulation of brain glutamate may underly the disorder. A low-trapping NMDA antagonist can restore glutamate equilibrium without causing new and serious side effects.

EuMentis is developing noncompetitive, low-trapping glutamate antagonists designed to inhibit receptors on neurons that are overly active. EuMentis is combining this clinically-validated approach with novel imaging technology to identify patients with ASD who are most likely to benefit.

Company website